Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Helen E White, Matthew Salmon, Francesco Albano, Christina Søs Auður Andersen, Stefan Balabanov, Gueorgui Balatzenko, Gisela Barbany, Jean-Michel Cayuela, Nuno Cerveira, Pascale Cochaux, Dolors Colomer, Daniel Coriu, Joana Diamond, Christian Dietz, Stéphanie Dulucq, Marie Engvall, Georg N Franke, Egle Gineikiene-Valentine, Michal Gniot, María Teresa Gómez-CasaresEnrico Gottardi, Chloe Hayden, Sandrine Hayette, Andreas Hedblom, Anca Ilea, Barbara Izzo, Antonio Jiménez-Velasco, Tomas Jurcek, Veli Kairisto, Stephen E Langabeer, Thomas Lion, Nora Meggyesi, Semir Mešanović, Luboslav Mihok, Gerlinde Mitterbauer-Hohendanner, Sylvia Moeckel, Nicole Naumann, Olivier Nibourel, Elisabeth Oppliger Leibundgut, Panayiotis Panayiotidis, Helena Podgornik, Christiane Pott, Inmaculada Rapado, Susan J Rose, Vivien Schäfer, Tasoula Touloumenidou, Christopher Veigaard, Bianca Venniker-Punt, Claudia Venturi, Paolo Vigneri, Ingvild Vorkinn, Elizabeth Wilkinson, Renata Zadro, Magdalena Zawada, Hana Zizkova, Martin C Müller, Susanne Saussele, Thomas Ernst, Katerina Machova Polakova, Andreas Hochhaus, Nicholas C P Cross*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstract

Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the use of secondary, lyophilized cell-based BCR::ABL1 reference panels traceable to the World Health Organization primary reference material to standardize and validate local laboratory tests. Panels were used to assign and validate conversion factors (CFs) to the International Scale and assess the ability of laboratories to assess deep molecular response (DMR). The study also explored aspects of internal quality control. The percentage of EUTOS reference laboratories (n = 50) with CFs validated as optimal or satisfactory increased from 67.5% to 97.6% and 36.4% to 91.7% for ABL1 and GUSB, respectively, during the study period and 98% of laboratories were able to detect MR4.5 in most samples. Laboratories with unvalidated CFs had a higher coefficient of variation for BCR::ABL1IS and some laboratories had a limit of blank greater than zero which could affect the accurate reporting of DMR. Our study indicates that secondary reference panels can be used effectively to obtain and validate CFs in a manner equivalent to sample exchange and can also be used to monitor additional aspects of quality assurance.

OriginalsprogEngelsk
Sider (fra-til)1834-1842
Antal sider9
TidsskriftLeukemia
Vol/bind36
Udgave nummer7
Tidlig onlinedato25 maj 2022
DOI
StatusUdgivet - jul. 2022

Bibliografisk note

© 2022. The Author(s).

Fingeraftryk

Udforsk hvilke forskningsemner 'Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study' indeholder.

Citationsformater